5 Pharmaceutical Stocks to Buy According to Jim Simons’ Euclidean Capital

Page 1 of 5

Below is the list of 5 pharmaceutical stocks to buy according to Jim Simons’ Euclidean Capital. For Jim Simons’ investment strategy, historical performance, and detailed discussion about his family office portfolio, please see 10 Pharmaceutical Stocks to Buy According to Jim Simons’ Euclidean Capital.

5. RAPT Therapeutics, Inc. (NASDAQ:RAPT)

Euclidean Capital’s Stake Value: $23.39 million

Percentage of Euclidean Capital’s 13F Portfolio: 5.46%

Number of Hedge Fund Holders: 21

Shares of RAPT Therapeutics, Inc. (NASDAQ:RAPT), a clinical-stage immunology-based biotechnology company, surged 59% since the beginning of this year, with most of the rally coming in the past three months amid positive results for RPT193 in early-stage atopic dermatitis study.

Page 1 of 5